Kras-driven heterotopic tumor development from hepatobiliary organoids

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Biliary tract cancers are difficult to treat with current therapies.
• Existing mouse models for biliary cancers are limited and challenging to develop.
• Targeting specific genes in the liver or gallbladder for cancer modeling is problematic.

Purpose of the Study:

• To establish a rapid, cell-based method for creating biliary tract cancer models.
• To investigate the genetic drivers of biliary carcinogenesis.
• To provide a resource for developing new biliary cancer therapeutics.

Main Methods:

• Primary murine liver and gallbladder organoids were genetically modified using lentiviral vectors.
• Organoids were engineered to carry common genetic alterations found in biliary tract cancers.
• Modified organoids were implanted into immunodeficient mice to induce tumor formation.

Main Results:

• Co-expression of mutant Kras and suppressed tumor suppressors rapidly induced biliary tract tumors within two months.
• Tumor progression mimicked multistep carcinogenesis, from normal to adenocarcinoma.
• Specific oncogenes like mutant Pik3ca and FGFR2-AHCYL1 fusion showed modest tumor-driving effects in liver organoids.

Conclusions:

• A novel ex vivo cell-based approach can efficiently generate biliary tract cancer models.
• This method facilitates the study of biliary carcinogenesis and the identification of therapeutic targets.
• The developed models offer a valuable platform for preclinical drug discovery in biliary cancers.